It Was Already A Gory Day For Blood-Testing Stocks — Then, Natera And Guardant Reported
Investor's Business Daily · ALLISON GATLIN ·
Shares of both plummeted following their third-quarter reports.
Blood-testing outfits Guardant Health (GH) and Natera (NTRA) beat Wall Street's third-quarter sales expectations late Thursday. But both stocks took a header, extending their regular-session losses. The duo are locked in one of fiercest rivalries in the blood-testing realm. They offer liquid biopsies that scan the blood for pieces of cancer. And both took a tumble Thursday after another blood…
It Was Already A Gory Day For Blood-Testing Stocks — Then, Natera And Guardant Reported
Read the full story at Investor's Business Daily · All coverage of this story